Articles On CogState (ASX:CGS)

Highlights Undervalued ASX stocks gaining renewed market attention Mining, tech, and financial sectors showing valuation gaps Strong cash flows helping identify long-term value The ASX 200 is reflecting a cautious tone as the broa...

Highlights Lithium and rare earth stocks regain strong market attention Technical trends signal improving sentiment across key players Broader resource momentum reshapes sector outlook The evolving momentum across the [ASX 200] is...

Highlights Undervalued ASX stocks gaining attention Tech and financial firms show strong outlook Market volatility reveals pricing gaps Undervalued Australian stocks across diverse sectors highlight opportunities driven by innovat...

Highlights Australian tech firms continue to expand through innovation AI-driven healthcare solutions are gaining traction Digital platforms are reshaping multiple industries Australia’s technology sector is evolving at pace, even...

Highlights Select stocks gaining attention for valuation gaps Diverse sectors from tech to retail in spotlight Market sentiment remains cautious yet opportunity-driven ASX stocks are drawing attention for valuation gaps across mul...

If you are on the lookout for some investment ideas, then read on. That's because Bell Potter has been busy picking out its best ideas for April from the smaller side of the market. Listed below are two more ASX shares that the broker has...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Cogstate Ltd (ASX: CGS) shares are in focus today after a big climb yesterday.  The ASX healthcare stock was one of many ASX shares to enjoy a strong rebound after President Trump set a deadline for Iran to reopen the Strait of Hormuz....

After already delivering a standout 12-month run, Cogstate Ltd (ASX: CGS) shares are back in the green on Wednesday. The gain follows a quarterly business update that highlighted continued strength in clinical trial contract activity and...

Highlights Australian biotech firms advance platelet freezing and medical technologies. Clinical trial progress and regulatory submissions shape sector activity. Healthcare companies reflect innovation across diagnostics and...

Cryopreserver Vitrafy reports initial success in a collaborative study with the US military Cogstate knocks ‘em for six with sales orders Heart play Imricor eyes US paediatric expansion   Cryopreserver Vitrafy Life Sciences (ASX:VFY) has...

Earnings season was brutal. At the smaller end of the market, three ASX small cap winners stood out, delivering encouraging numbers. Reporting season volatility ramped up again in February. Volatility, though, for the smaller end of the mar...

The S&P/ASX 200 Index (ASX: XJO) is having one of its worst sessions in a long time on Monday. At the time of writing, the benchmark index is down 4.1% to 8,487.2 points. Four ASX shares that have managed to avoid the selloff are liste...

If you are looking for new investment ideas this month, then it could pay to listen to what Bell Potter is saying. That's because the broker has just released its latest top Australian picks from the smaller side of the market. These are it...

Clinical trial company Cogstate Ltd (ASX: CGS) reported its half-year results last week, and it's making at least one broker sit up and notice. The team at Canaccord Genuity has had a look at the result and likes what they see, reiterati...

The ASX healthcare sector fell 0.73% this week as reporting season continued Pathology and radiology provider Sonic Healthcare rises with H1 results ahead of expectations Morgans lifts its target price for protective gear maker Ansell afte...

Two ASX small caps that enjoyed big gains this earnings season are Cogstate Ltd (ASX: CGS) and Austco Healthcare Ltd (ASX: AHC).  Both companies released half-year results this week, leading to massive share price gains.  Let's see wh...

If you are wanting some exposure to the smaller side of the market, then it could be worth considering the ASX All Ords stock in this article. That's the view of analysts at Bell Potter, who have just slapped a buy rating on its shares. Whi...

Highlights Emerging ASX penny stocks gaining renewed market attention Resource and technology companies showing operational progress Market trends shaping small-cap opportunities across Australia This article explores...

The S&P/ASX 200 Index (ASX: XJO) is back on form and charging higher on Thursday. In afternoon trade, the benchmark index is up 0.6% to 8,835.2 points. Four ASX shares that are rising more than most today are listed below. Here's why...

Healthcare slides 1.3% for the week despite the wider market lifting 0.7% Immutep surges 46% on lucrative global licensing deal with Dr. Reddy’s PolyNovo wins Morgans upgrade as new leadership team takes charge   Healthcare and life scien...

Highlights Flat index hid sharp falls in healthcare and micro-caps Guidance resets and funding concerns drove heavy repricing Higher yields continued to pressure long-duration stories A calm ASX headline masked sharp d...

Cogstate shares plunge on revenue and earnings downgrade Immuron shares have the runs after failed US military trial Was Immutep’s share price reaction underdone?   CogState (ASX:CGS) shares have tumbled as much as 30% on the back of a r...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to record a small decline. At the time of writing, the benchmark index is down 0.25% to 8,565.4 points. Four ASX shares that are falling more than most today are listed b...

The market may be edging higher today, but the same cannot be said for the ASX All Ords share in this article. In morning trade, investors have sold this share down by as much as 30% to $1.75. Which ASX All Ords share? The share that is cra...

ASX health sector fell 1.8% for the week, while broader market dropped 3.86% in the same period  FDA confirms Animal Rule and PRV potential for Island Pharmaceutical’s Galidesivir in Marburg Clever Culture identifies more than $45 million...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

The ASX health sector moved up 1.30% for the week, while the broader market inched up 0.12% Aroa recorded fourth consecutive quarter of positive net cash flow with Myriad breaking records Orthocell raised $30 million in oversubscribed plac...

The NSW Supreme Court has, in effect, ruled against Cosette’s attempt to abandon its $670m takeover of Mayne Pharma Cogstate posts record quarterly sales on the back of surging demand for depression and schizophrenia testing Aroa posts st...

ASX small-cap shares are some of the most exciting investments because of the excellent compounding potential.   A business like Commonwealth Bank of Australia (ASX: CBA) may find it challenging to double its profit quickly because of ho...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week, including HealthInvest 2025. Second HealthInvest 2025 event in Sy...

ASX heath sector falls 1.09% over past five days, while broader markets down 0.66% for same period Study shows PolyNovo’s NovoSorb BTM accelerates healing of large post-surgical diabetes-related foot wounds  Stockhead to join with IR Depar...

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on September 24 This event will highlight some of ASX’s leading up-and-coming health and life sciences companies Clever Culture Systems, Cogstate, EBR Systems,...

The Cogstate Ltd (ASX:CGS) share price is climbing 5% on Friday after the neuroscience technology company posted its FY25 results. The shares opened higher this morning and have maintained gains as investors digest the company's numbers...

Highlights Key earnings updates from small-to-mid cap companies Inghams results show weaker performance outlook Cuscal expands with strategic acquisition The trading session opened with several small-to-mid cap companies releasing...

Morgans’ Scott Power describes mood at Bioshares Biotech Summit as “markedly more upbeat than prior years” with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-te...

ASX falls 8.4 points, which was about 0.1% Xero sheds 4.7% on $3.9b acquisition of Melio Payments Info tech sector slumps 2%   ASX edges lower on Xero acquisition The ASX 200 has fallen 8.4 points or 0.1% in trade today, after major infor...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 8,560.3 points. Four ASX shares that are rising more than most today are listed below. He...

The ASX All Ordinaries index is having a strong session on Tuesday. In morning trade, the widely followed index is up 1.1% to 8,786.2 points. This has been driven by news of a ceasefire between Israel and Iran. One ASX All Ords stock that i...

ASX medtechs are taking brain diagnostics beyond the hospital or clinical settings to the front lines of care EMVision’s First Responder portable brain scanning technology aims to speed up stroke detection for better patient outcomes Cogst...

Highlights ASX200 closes with a minor dip, but Energy and Real Estate sectors lead Penny stocks gain attention, offering growth opportunities Beamtree Holdings (BMT) stands out in the healthcare space The Australian ma...

Highlights: ASX market activity points to an upward shift, with the main index aiming for a key milestone. Companies across various industries demonstrate resilience, with smaller stocks displaying growth. Financial performance and ma...

Nanosonics says it’s on track to release its much-awaited next-generation anti-infection device this year Cogstate’s earnings driven by Alzheimer’s disease trials growth  Sonic hoists profit by 17% but there’s no share price boom   Hospit...

Highlights ASX-listed companies are shaping the future of sports technology through innovative solutions for athlete performance and safety. CogState (ASX:CGS), HitIQ (ASX:HIQ), Control Bionics (ASX:CBL), and Catapult Group (ASX:CAT) a...

Several ASX-listed companies are driving advancements in the growing sports technology sector  CogState is working to optimise brain health assessments for various conditions including concussion Control Bionics is unlocking growth in spor...

EBR expects US approval of its Wise wireless pacemaker lead by April 13 Cogstate benefits from bolstered funding for US clinical trials Investors vie over the future of Percheron Therapeutics after its trial flop   EBR Systems (ASX:EBR) e...

Highlights EBR Systems (ASX:EBR) anticipates FDA approval for its Wise pacemaker lead by April 13, paving the way for commercial launch in late 2023. Cogstate (ASX:CGS) reports a 19% increase in revenue due to improved US biotech fundi...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Cogstate falls 7pc as clinical trials pipeline declines LBT Innovations delivers its technology to Thermo Fisher   Cogstate down after pipeline contracts Neuroscience biotech, Cogstate (ASX:CGS), tumbled by as much as -10% this morning af...

Last weekend a menagerie of lions, magpies, panthers and broncos battled for the silverware across our two major football codes. (Sorry Queensland. Twice!) How do investors get closer to the action, other than invading the pitch? While Aust...